| __timestamp | ImmunityBio, Inc. | Neurocrine Biosciences, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 4326000 | 17986000 |
| Thursday, January 1, 2015 | 226206000 | 32480000 |
| Friday, January 1, 2016 | 94391000 | 68081000 |
| Sunday, January 1, 2017 | 53821000 | 169906000 |
| Monday, January 1, 2018 | 35463000 | 248932000 |
| Tuesday, January 1, 2019 | 46456000 | 354100000 |
| Wednesday, January 1, 2020 | 71318000 | 433300000 |
| Friday, January 1, 2021 | 135256000 | 583300000 |
| Saturday, January 1, 2022 | 102708000 | 752700000 |
| Sunday, January 1, 2023 | 129620000 | 887600000 |
| Monday, January 1, 2024 | 1007200000 |
Data in motion
In the competitive world of biotechnology, managing costs is crucial for success. This chart compares the Selling, General, and Administrative (SG&A) expenses of Neurocrine Biosciences, Inc. and ImmunityBio, Inc. from 2014 to 2023. Over this period, Neurocrine Biosciences consistently outpaced ImmunityBio in SG&A spending, with a peak in 2023 where their expenses were nearly 7 times higher than ImmunityBio's. This trend highlights Neurocrine's aggressive investment in administrative and sales functions, possibly reflecting a strategy to expand market presence and drive growth. Meanwhile, ImmunityBio's more conservative spending approach may indicate a focus on cost efficiency or a different growth strategy. Understanding these financial strategies provides valuable insights into how these companies navigate the biotech landscape, balancing innovation with fiscal responsibility.
Who Optimizes SG&A Costs Better? Sanofi or ImmunityBio, Inc.
SG&A Efficiency Analysis: Comparing Zoetis Inc. and Neurocrine Biosciences, Inc.
Who Optimizes SG&A Costs Better? Alnylam Pharmaceuticals, Inc. or ImmunityBio, Inc.
Breaking Down SG&A Expenses: Neurocrine Biosciences, Inc. vs Dr. Reddy's Laboratories Limited
Neurocrine Biosciences, Inc. vs Exelixis, Inc.: SG&A Expense Trends
Comparing SG&A Expenses: Neurocrine Biosciences, Inc. vs Ionis Pharmaceuticals, Inc. Trends and Insights
Cost Management Insights: SG&A Expenses for Neurocrine Biosciences, Inc. and Amneal Pharmaceuticals, Inc.
Selling, General, and Administrative Costs: Neurocrine Biosciences, Inc. vs ACADIA Pharmaceuticals Inc.
Neurocrine Biosciences, Inc. or Supernus Pharmaceuticals, Inc.: Who Manages SG&A Costs Better?
Who Optimizes SG&A Costs Better? Bio-Techne Corporation or ImmunityBio, Inc.
Breaking Down SG&A Expenses: Xenon Pharmaceuticals Inc. vs ImmunityBio, Inc.
ImmunityBio, Inc. or Soleno Therapeutics, Inc.: Who Manages SG&A Costs Better?